Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Articles online first > Journal of Neurosurgical Sciences 2018 Feb 13

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

JOURNAL OF NEUROSURGICAL SCIENCES

A Journal on Neurosurgery


Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,522


eTOC

 

Journal of Neurosurgical Sciences 2018 Feb 13

DOI: 10.23736/S0390-5616.18.04081-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes

Sajad H. ARIF 1 , Arshad A. PANDITH 2, Rehana TABASUM 3, Altaf U. RAMZAN 1, Sarabjeet SINGH 1, Mushtaq A. SIDDIQI 4, Abdul R. BHAT 1

1 Department of Neurosurgery, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India; 2 Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India; 3 Department of Pharmacology, Government Medical Collage, Srinagar, Kashmir, India; 4 Immunology and Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India


PDF  


INTRODUCTION: We aimed to assess the effect of antityrosine kinase inhibitors (Geftinib) in overall survival of the GBM patients in the backdrop of mutational status of EGFR and PTEN genes.
MATERIALS AND METHODS: All the patients subjected to resection or biopsies were put on Geftinib and radiotherapy was delivered as per the hospital protocol. EGFR and PTEN mutational spectrum was performed by SSCP followed by DNA sequencing.
RESULTS: In total, 50% GBM tumors had mutation either in EGFR or PTEN. Median PFS and OS observed in patients with EGFR +ve/PTEN -ve was significantly favorable (P<0.05) which aggregated to 9(7, 11) months and 20(16, 24) months respectively than 6 (4, 8) months &13 (7, 19) months in patients with PTEN +ve/EGFR -ve. Patients positive forboth EGFR/PTEN had lower DFS and OS of 6 () & 9 () monthsas compared to 6(5, 7) and 14(12, 24) months for those negative for both EGFR/PTEN.
CONCLUSIONS: We conclude EGFR gene alterations with wildtype PTEN is associated with significantly better PFS and OS in patients treated with antityrosine kinase inhibitors (Gefitinib). Combined EGFR and PTEN gene mutation is associated with significantly poor response to Geftinib in terms of Median OS.


KEY WORDS: Glioblastoma multiforme - Anti-tyrosine kinases - Geftinib - DNA sequencing - Mutations - EGFR - PTEN

top of page

Publication History

Article first published online: February 13, 2018
Manuscript accepted: January 24, 2018
Manuscript revised: January 16, 2018
Manuscript received: May 11, 2017

Cite this article as

Arif SH, Pandith AA, Tabasum R, Ramzan AU, Singh S, Siddiqi MA, et al. Significant effect of antityrosine kinase inhibitor (Gefitinib) on overall survival of the Glioblastoma (GBM) patients in the backdrop of mutational status of EGFR and PTEN genes. J Neurosurg Sci 2018 Feb 13. DOI: 10.23736/S0390-5616.18.04081-X

Corresponding author e-mail

sajadarif.neuro@gmail.com